Mizuho lowered shares of Pacira Pharmaceuticals (NASDAQ:PCRX) from a buy rating to a neutral rating in a research note issued to investors on Wednesday morning, Marketbeat reports. They currently have $44.00 price objective on the stock, down from their previous price objective of $53.00.
Several other research analysts have also recently weighed in on PCRX. BMO Capital Markets raised their target price on Pacira Pharmaceuticals from $38.00 to $39.00 and gave the company a market perform rating in a research note on Wednesday, November 8th. Jefferies Group decreased their target price on Pacira Pharmaceuticals to $52.00 and set a buy rating for the company in a research note on Thursday, November 9th. HC Wainwright reaffirmed a buy rating and set a $52.00 target price on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Wedbush reaffirmed a buy rating and set a $80.00 target price on shares of Pacira Pharmaceuticals in a research note on Monday, November 20th. Finally, Oppenheimer reaffirmed a hold rating on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $48.86.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at $45.25 on Wednesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99. Pacira Pharmaceuticals has a fifty-two week low of $29.81 and a fifty-two week high of $58.95.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The business’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.20 EPS. equities analysts predict that Pacira Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.
In related news, SVP James B. Jones sold 850 shares of the stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $41.11, for a total value of $34,943.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David M. Stack sold 58,885 shares of the stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the completion of the sale, the chief executive officer now directly owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The disclosure for this sale can be found here. Insiders sold a total of 69,735 shares of company stock valued at $2,692,594 in the last quarter. 6.60% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the stock. HealthCor Management L.P. raised its stake in shares of Pacira Pharmaceuticals by 63.1% during the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock worth $85,564,000 after purchasing an additional 693,799 shares in the last quarter. Eaton Vance Management purchased a new stake in shares of Pacira Pharmaceuticals during the 2nd quarter worth about $19,519,000. Mesirow Financial Investment Management Equity Management purchased a new stake in shares of Pacira Pharmaceuticals during the 3rd quarter worth about $14,671,000. Stonepine Capital Management LLC purchased a new stake in shares of Pacira Pharmaceuticals during the 3rd quarter worth about $14,089,000. Finally, Epoch Investment Partners Inc. raised its stake in shares of Pacira Pharmaceuticals by 195.7% during the 3rd quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock worth $20,127,000 after purchasing an additional 354,728 shares in the last quarter.
WARNING: “Pacira Pharmaceuticals (PCRX) Downgraded by Mizuho” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://transcriptdaily.com/2017/12/03/pacira-pharmaceuticals-pcrx-downgraded-by-mizuho.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.